These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7535417)

  • 1. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R; Elkind NB; Ronen D; Rotter V
    Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis.
    Erez-Alon N; Herkel J; Wolkowicz R; Ruiz PJ; Waisman A; Rotter V; Cohen IR
    Cancer Res; 1998 Dec; 58(23):5447-52. PubMed ID: 9850078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA.
    Herkel J; Kam N; Erez N; Mimran A; Heifetz A; Eisenstein M; Rotter V; Cohen IR
    Eur J Immunol; 2004 Dec; 34(12):3623-32. PubMed ID: 15495163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PAb240+ conformation of wild type p53 binds DNA.
    McLure KG; Lee PW
    Oncogene; 1996 Sep; 13(6):1297-303. PubMed ID: 8808704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
    Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
    Oncogene; 1995 Jan; 10(2):389-93. PubMed ID: 7530828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding.
    Cesková P; Chichger H; Wallace M; Vojtesek B; Hupp TR
    J Mol Biol; 2006 Mar; 357(2):442-56. PubMed ID: 16438982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific DNA binding by different classes of human p53 mutants.
    Rolley N; Butcher S; Milner J
    Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs.
    Hecker D; Page G; Lohrum M; Weiland S; Scheidtmann KH
    Oncogene; 1996 Mar; 12(5):953-61. PubMed ID: 8649812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
    Hainaut P; Milner J
    Cancer Res; 1993 Oct; 53(19):4469-73. PubMed ID: 8402615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb.
    Simons A; Melamed-Bessudo C; Wolkowicz R; Sperling J; Sperling R; Eisenbach L; Rotter V
    Oncogene; 1997 Jan; 14(2):145-55. PubMed ID: 9010216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunochemical evidence of a mutated p53 protein expressed in human colorectal adenocarcinoma].
    Hammel PR; Beuvon FX; Salmon RJ; Remvikos Y
    Gastroenterol Clin Biol; 1991; 15(6-7):529-35. PubMed ID: 1916131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization and fine mapping of antigenic sites on the nucleocapsid protein N of porcine reproductive and respiratory syndrome virus with monoclonal antibodies.
    Meulenberg JJ; van Nieuwstadt AP; van Essen-Zandbergen A; Bos-de Ruijter JN; Langeveld JP; Meloen RH
    Virology; 1998 Dec; 252(1):106-14. PubMed ID: 9875321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 represses Sp1 DNA binding and HIV-LTR directed transcription.
    Bargonetti J; Chicas A; White D; Prives C
    Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):935-49. PubMed ID: 9449526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display.
    Coomber DW; Ward RL
    Clin Cancer Res; 2001 Sep; 7(9):2802-8. PubMed ID: 11555596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma.
    Yuwen H; Hsia CC; Nakashima Y; Evangelista A; Tabor E
    Biochem Biophys Res Commun; 1997 May; 234(1):194-7. PubMed ID: 9168988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence-specific interaction of a conformational domain of p53 with DNA.
    Srinivasan R; Roth JA; Maxwell SA
    Cancer Res; 1993 Nov; 53(22):5361-4. PubMed ID: 8221671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation.
    Medcalf EA; Milner J
    Oncogene; 1993 Oct; 8(10):2847-51. PubMed ID: 7690928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.